Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 5/20 | 0.68 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.68 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.68 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.62 |
| ▸ | GAA | P10253 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 5/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.56 |
| ▸ | ALPL | P05186 | 1/20 | 0.54 |
| ▸ | ALPG | P10696 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30775585 | 1.00 | CHRM2 (0.68) | CHRM2CHRM4CHRM1CHRM3ALDH1A1 | |
| SCHEMBL1102038 | 0.95 | CHRM2 (0.70) | CHRM2CHRM4CHRM1CHRM3ALDH1A1 | |
| SCHEMBL5152882 | 0.88 | MEN1 (0.71) | CHRM2CHRM4CHRM1CHRM3ALDH1A1 | |
| SCHEMBL8981985 | 0.86 | CHRM2 (0.67) | CHRM2CHRM4CHRM1CHRM3ALDH1A1 | |
| SCHEMBL13444609 | 0.83 | ALDH1A1 (0.54) | CHRM2CHRM4CHRM1CHRM3ALDH1A1 | |
| SCHEMBL29930459 | 0.81 | CHRM2 (1.00) | CHRM2CHRM4CHRM1CHRM3ALDH1A1 | |
| SCHEMBL28643439 | 0.81 | CHRM2 (1.00) | CHRM2CHRM4CHRM1CHRM3ALDH1A1 | |
| SCHEMBL11671841 | 0.81 | ALPL (0.70) | CHRM2CHRM4CHRM1CHRM3ALDH1A1 | |
| SCHEMBL9974151 | 0.81 | CHRM2 (0.68) | CHRM2CHRM4CHRM1CHRM3ALDH1A1 | |
| SCHEMBL4700798 | 0.81 | ALDH1A1 (0.71) | CHRM2CHRM4CHRM1CHRM3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100173896-A1 | Organic Compounds | SAKAKI JUNICHI | 2010-07-08 | — | — | US | disclosed |
| US-20100130469-A1 | 2, 6-NAPHTHRIDINE DERIVATIVES | VAN EIS MAURICE | 2010-05-27 | — | — | US | disclosed |
| US-7709470-B2 | 11-phenyl-dibenzodiazepine derivatives as RXR-antagonists | NOVARTIS AG (CH) | 2010-05-04 | — | — | US | disclosed |
| EP-1859802-A2 | Compositions comprising benzo(G)quinoline derivates and prostaglandin derivates | Novartis AG (CH) | 2007-11-28 | — | — | EP | disclosed |
| US-20070093507-A1 | Compositions comprising benzo (g) quinoline derivatives and prostaglandin derivatives | LAMBROU GEORGE N | 2007-04-26 | — | — | US | disclosed |
| US-20070043029-A1 | 11-Phenyl-dibenzodiazepine derivatives as rxr-antagonists | NOVARTIS AG (CH) | 2007-02-22 | — | — | US | disclosed |
| EP-1663230-A1 | COMPOSITIONS COMPRISING BENZO(G)QUINOLINE DERIVATIVES AND PROSTAGLANDIN DERIVATIVES | Novartis AG (CH) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005023258-A1 | COMPOSITIONS COMPRISING BENZO (G) QUINOLINE DERIVATIVES AND PROSTAGLANDIN DERIVATIVES | NOVARTIS AG (CH) | 2005-03-17 | — | — | WO | disclosed |
| US-6080743-A | AS CHEMICAL INTERMEIDATES FOR PREPARING DRUGS | NOVARTIS AG (CH) | 2000-06-27 | — | — | US | disclosed |
| EP-0853617-A1 | NOVEL 2,3-DIOXO-1,2,3,4-TETRAHYDRO-QUINOYXALINYL DERIVATIVES | Novartis AG (CH) | 1998-07-22 | — | — | EP | disclosed |
| WO-1997008155-A1 | NOVEL 2,3-DIOXO-1,2,3,4-TETRAHYDRO-QUINOYXALINYL DERIVATIVES | NOVARTIS AG (CH) | 1997-03-06 | — | — | WO | disclosed |
| EP-0292923-A2 | Piperidine compounds and pharmaceutical uses thereof | Yoshitomi Pharmaceutical Industries, Ltd. (JP) | 1988-11-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043029-A1 | 11-Phenyl-dibenzodiazepine derivatives as rxr-antagonists | RXRB, RXRA, RXRG | CHRM2 911/4885CHRM4 824/4885CHRM1 1076/4885 |
| US-20100130469-A1 | 2, 6-NAPHTHRIDINE DERIVATIVES | PKN1, PKN2, CDK9 | CHRM2 2750/4885CHRM4 2639/4885CHRM1 2336/4885 |
| US-20070093507-A1 | Compositions comprising benzo (g) quinoline derivatives and prostaglandin derivatives | PTGIS, PTGES, PTGS2 | CHRM2 967/4885CHRM4 959/4885CHRM1 1282/4885 |
| US-20100173896-A1 | Organic Compounds | RXRB, RXRA, RXRG | CHRM2 562/4885CHRM4 259/4885CHRM1 536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.